Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

14.05USD
12 Sep 2014
Price Change (% chg)

$-0.90 (-6.02%)
Prev Close
$14.95
Open
$14.96
Day's High
$15.02
Day's Low
$13.66
Volume
59,209
Avg. Vol
51,208
52-wk High
$47.18
52-wk Low
$10.51

STML.OQ

Chart for STML.OQ

About

Stemline Therapeutics, Inc. (Stemline) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds... (more)

Overall

Beta: --
Market Cap (Mil.): $186.28
Shares Outstanding (Mil.): 13.26
Dividend: --
Yield (%): --

Financials

  STML.OQ Industry Sector
P/E (TTM): -- 148.78 33.52
EPS (TTM): -2.21 -- --
ROI: -36.01 -3.25 17.33
ROE: -36.12 -7.86 18.19
Search Stocks

Competitors

  Price Change
Astellas Pharma Inc (4503.T) ¥1,594 +49.50
Eisai Co., Ltd (4523.T) ¥4,350 +4.50
Sumitomo Dainippon Pharma Co Ltd (4506.T) ¥1,363 -12.00
Pfizer Inc. (PFE.N) $29.43 -0.20
Novartis AG (NOVN.VX) CHF87.40 -0.20
Merck & Co., Inc. (MRK.N) $59.55 -0.55
Roche Holding Ltd. (ROG.VX) CHF276.10 +1.40
Sanofi SA (SASY.PA) €86.89 0.00
GlaxoSmithKline plc (GSK.L) 1,430.00p -11.00
Amgen, Inc. (AMGN.OQ) $137.89 -1.07

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks